Caplin Point Laboratories has attached a Press Release regarding grant of final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) TIMOPTIC, from Bausch and Lomb Inc, to its Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.